Infant Bacterial Therapeutics

Quick facts

Phase 3 pipeline

• IBP-9414 · Immunology / Infectious Disease / Pediatrics
  IBP-9414 is a live biotherapeutic product designed to restore beneficial bacterial populations in the infant microbiome.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Infant Bacterial Therapeutics portfolio CI brief
• Infant Bacterial Therapeutics pipeline updates RSS